Updates in adjuvant systemic therapy for melanoma
M Kwak, NE Farrow, AKS Salama… - Journal of surgical …, 2019 - Wiley Online Library
Journal of surgical oncology, 2019•Wiley Online Library
There has been a rapid increase in adjuvant therapies approved for treatment following
surgical resection of stages III/IV melanoma. We review current indications for adjuvant
therapy, which currently includes a heterogenous group of stages III and IV patients with
melanoma. We describe several pivotal clinical trials of systemic immune therapies, targeted
immune therapies, and adjuvant vaccine strategies. Finally, we discuss the evidence for
selecting the most appropriate treatment regimen (s) for the individual patient.
surgical resection of stages III/IV melanoma. We review current indications for adjuvant
therapy, which currently includes a heterogenous group of stages III and IV patients with
melanoma. We describe several pivotal clinical trials of systemic immune therapies, targeted
immune therapies, and adjuvant vaccine strategies. Finally, we discuss the evidence for
selecting the most appropriate treatment regimen (s) for the individual patient.
There has been a rapid increase in adjuvant therapies approved for treatment following surgical resection of stages III/IV melanoma. We review current indications for adjuvant therapy, which currently includes a heterogenous group of stages III and IV patients with melanoma. We describe several pivotal clinical trials of systemic immune therapies, targeted immune therapies, and adjuvant vaccine strategies. Finally, we discuss the evidence for selecting the most appropriate treatment regimen(s) for the individual patient.
Wiley Online Library以上显示的是最相近的搜索结果。 查看全部搜索结果